PureTech Health (PRTC) Cash & Equivalents (2019 - 2025)

PureTech Health (PRTC) has 7 years of Cash & Equivalents data on file, last reported at $277.3 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $277.3 million, down 24.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $277.3 million (down 24.5% YoY), and the FY2025 annual result was $277.3 million, down 24.5% from the prior year.
• Cash & Equivalents rose to $277.3 million in Q4 2025 per PRTC's latest filing, from $260.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $465.7 million in Q4 2021 and troughed at $149.9 million in Q4 2022.
• A 5-year average of $288.6 million and a median of $277.3 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 67.82% in 2022, then surged 92.23% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $465.7 million in 2021, then sank by 67.82% to $149.9 million in 2022, then rose by 27.5% to $191.1 million in 2023, then surged by 92.23% to $367.3 million in 2024, then decreased by 24.5% to $277.3 million in 2025.
• Business Quant data shows PRTC's Cash & Equivalents at $277.3 million in Q4 2025, $260.6 million in Q2 2025, and $367.3 million in Q4 2024.